Dyne Therapeutics, Inc. (DYN) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $18.00: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.9/10 and A.R:R 7.3:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 17%; Elevated put/call ratio: 28.11; Below-average business quality.
Dyne Therapeutics is a clinical-stage biotech developing FORCE platform-based therapeutics for neuromuscular diseases, with lead assets z-rostudirsen (DYNE-251) for DMD exon 51 skipping and z-basivarsen (DYNE-101) for DM1. BLA submission for z-rostudirsen planned Q2 2026 for... Read more
Sell if holding. Engine safety override at $18.00: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.9/10 and A.R:R 7.3:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 17%; Elevated put/call ratio: 28.11; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Score 4.9/10, moderate confidence.
Passes 6/7 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, earnings proximity 48d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: aggressive.
Recent developments
updated 2026-06-10Recent Developments — Dyne Therapeutics, Inc.
Latest news
- NEWS Dyne Therapeutics Completes Enrollment In Registrational Expansion Cohort Of Phase 1/2 ACHIEVE Trial Of Zeleciment Basiv — benzinga Jun 3, 2026 positive
- NEWS Dyne Therapeutics Submits Biologics License Application To FDA For Zeleciment Rostudirsen To Duchenne Muscular Dystrophy — benzinga May 26, 2026 positive
- NEWS Dyne Therapeutics Initiates Phase 3 FORZETTO Trial Of Zeleciment Rostudirsen In Individuals With Duchenne Muscular Dystr — benzinga May 20, 2026 positive
- NEWS Evercore ISI Group Maintains Outperform on Dyne Therapeutics, Lowers Price Target to $33 — benzinga May 15, 2026 positive
- NEWS Bernstein Maintains Market Perform on Dyne Therapeutics, Raises Price Target to $24 — benzinga May 13, 2026 positive
Generated 2026-06-15T18:11:46Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelinez-rostudirsen (DMD exon 51)10-K Item 1: 'We plan to submit a biologics license application, or BLA, to the U.S. Food and Drug Administration, or FDA, for U.S. Accelerated Approval of z-rostudirsen for DMD patients who have mutations amenable to exon 51 skipping in the second quarter of 2026'
- HIGHpipelinez-basivarsen (DM1)10-K Item 1: 'We plan to submit a BLA to the FDA for U.S. Accelerated Approval of z-basivarsen for DM1 patients early in the third quarter of 2027.'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers·2 ceiling hits
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Volatile — 6.3% daily ATR makes tight stops impractical. Position-size conservatively.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $18.00: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.9/10 and A.R:R 7.3:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 17%; Elevated put/call ratio: 28.11; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $16.67. Score 4.9/10, moderate confidence.
Take-profit target: $34.43 (+92.1% upside). Prior stop was $16.67. Stop-loss: $16.67.
Concentration risk — Pipeline: z-rostudirsen (DMD exon 51); Concentration risk — Pipeline: z-basivarsen (DM1); Quality below floor (1.6 < 4.0).
Dyne Therapeutics, Inc. trades at a P/E of N/A (forward -5.6). TrendMatrix value score: 9.0/10. Verdict: Sell.
20 analysts cover DYN with a consensus score of 4.2/5. Average price target: $38.
What does Dyne Therapeutics, Inc. do?Dyne Therapeutics is a clinical-stage biotech developing FORCE platform-based therapeutics for neuromuscular diseases,...
Dyne Therapeutics is a clinical-stage biotech developing FORCE platform-based therapeutics for neuromuscular diseases, with lead assets z-rostudirsen (DYNE-251) for DMD exon 51 skipping and z-basivarsen (DYNE-101) for DM1. BLA submission for z-rostudirsen planned Q2 2026 for U.S. Accelerated Approval; Phase 3 confirmatory trials for both programs planned in 2026.